Wall Street Zen lowered shares of Septerna (NASDAQ:SEPN – Free Report) from a hold rating to a sell rating in a report released on Saturday morning,Wall Street Zen reports.
Several other research analysts also recently weighed in on SEPN. Wells Fargo & Company upped their target price on shares of Septerna from $50.00 to $61.00 and gave the company an “overweight” rating in a research note on Wednesday, November 4th. Stifel Nicolaus raised their price target on shares of Septerna from $49.00 to $60.00 and gave the company a “buy” rating in a report on Tuesday, November 10th. Guggenheim lifted their price target on shares of Septerna from $51.00 to $65.00 and gave the stock a “buy” rating in a research note on Friday, November 6th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Septerna in a report on Thursday, October 15th. Finally, Raymond James Financial reissued a “strong-buy” rating and issued a $49.00 price objective on shares of Septerna in a research report on Tuesday, August 11th. One analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $56.44.
View Our Latest Stock Analysis on Septerna
Septerna Trading Down 2.2%
Shares of Septerna stock opened at $41.67 on Friday. The stock has a market capitalization of $1.98 billion, a P/E ratio of -32.30 and a beta of 2.20. The business’s fifty day moving average price is $40.56 and its 200 day moving average price is $33.21. Septerna has a twelve month low of $21.31 and a twelve month high of $53.34.
Septerna (NASDAQ:SEPN – Get Free Report) last announced its quarterly earnings results on Monday, November 9th. The company reported ($0.57) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.42) by ($0.15). The company had revenue of $18.88 million during the quarter, compared to analyst estimates of $20.78 million. Septerna had a negative net margin of 61.29% and a negative return on equity of 14.98%. As a group, sell-side analysts predict that Septerna will post -1.45 EPS for the current year.
Insider Transactions at Septerna
In other news, COO Elizabeth Bhatt sold 4,000 shares of the business’s stock in a transaction dated Thursday, October 15th. The shares were sold at an average price of $37.41, for a total value of $149,640.00. Following the completion of the sale, the chief operating officer owned 174,209 shares of the company’s stock, valued at approximately $6,517,158.69. The trade was a 2.24% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Alan Ezekowitz sold 81,820 shares of the business’s stock in a transaction dated Wednesday, November 11th. The stock was sold at an average price of $48.09, for a total transaction of $3,934,723.80. Following the completion of the sale, the director directly owned 35,600 shares of the company’s stock, valued at $1,712,004. The trade was a 69.68% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 89,153 shares of company stock valued at $4,210,451. 5.80% of the stock is currently owned by corporate insiders.
Hedge Funds Weigh In On Septerna
Large investors have recently modified their holdings of the stock. TRV GP V LLC acquired a new stake in shares of Septerna during the 2nd quarter valued at approximately $208,160,143. TRV GP VI LLC bought a new position in Septerna during the second quarter worth $141,048,460. BlackRock Inc. acquired a new position in Septerna in the second quarter worth $64,706,000. Jupiter Topco LLC acquired a new position in Septerna in the second quarter worth $43,723,000. Finally, Primecap Management Co. CA bought a new stake in Septerna during the second quarter valued at $39,096,000.
Septerna Company Profile
Septerna is a clinical-stage biotechnology company developing medicines that target G protein-coupled receptors (GPCRs), a large family of proteins involved in many biological processes. The company is based in South San Francisco, California. Its discovery platform is designed to identify drug candidates that act on GPCRs, including targets that have been difficult to address with conventional drug-development approaches. Septerna is advancing candidates for endocrine, metabolic and other disease areas, with an emphasis on small-molecule medicines.
Further Reading
- Five stocks we like better than Septerna
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Septerna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Septerna and related companies with MarketBeat.com's FREE daily email newsletter.
